iPSC Companies

Allele Biotech is developing a diabetes drug created from iPSC-derived pancreatic beta cells.

Aspen Neuroscience is developing the world’s first autologous iPSC-derived neuron replacement therapy for Parkinson’s disease.

Avery Therapeutics and I Peace, Inc., are collaborating to advance an iPSC-derived cell therapeutic for heart failure.

Bayer acquired iPSC cell therapy company BlueRock Therapeutics in August 2019 to develop iPSC-derived therapies for ocular diseases, Parkinson’s disease, and heart failure.

BeiGene is pursuing iPSC-derived cell therapies focused on enhancing the potency of γδ and αβ T-cells for cancer treatment.

BlueRock Therapeutics develops iPSC-derived cell therapies for Parkinson’s disease, heart failure, and ocular diseases.

Bone Therapeutics has partnered with Implant Therapeutics to develop allogeneic iPSC-derived MSCs.

Brooklyn Immuno Therapeutics is developing iPSC-derived MSC products with gene editing technology for immune therapy.

Cartherics is creating genetically engineered iNK cells from iPSCs to target cancer.

CellOrigin Biotech (Hangzhou) Co, Ltd is developing allogeneic iPSC-derived CAR macrophages to treat cancer.

Cellectis is partnering with Cytovia Therapeutics to produce gene-edited iNK cells derived from iPSCs.

Cellistic is producing iPSC-derived CAR-NKT cells for cancer therapy.

Century Therapeutics develops iPSC-derived immune effector cell therapies for cancer and immune disorders.

Citius Pharmaceuticals uses iPSCs to create MSCs for allogeneic therapies, including in diabetes.

Clade Therapeutics is developing immune-cloaked iPSC-derived cell therapies for various diseases.

Cuorips Inc. is developing cardiac tissue sheets from iPSCs to treat coronary artery disease.

Creative Medical Technology Holdings, Inc. is developing iPSC-derived insulin-producing Islet Cells for diabetes treatment.

Cynata Therapeutics manufactures iPSC-derived MSCs for treating GvHD, osteoarthritis, and respiratory failure.

CytoMed Therapeutics develops iPSC-derived gamma delta natural killer T cells for cancer immunotherapy.

Cytovia Therapeutics is developing gene-edited, allogeneic iNK and CAR-iNK cells derived from iPSCs.

Edigene, Inc. and Neukio Biotherapeutics are co-developing allogeneic iPSC-derived NK cells for cancer therapy.

Editas Medicine is developing iPSC-derived natural killer cells for cancer treatment.

Eterna Therapeutics is developing gene-edited iPSCs for immune responses and hematopoietic regeneration.

Exacis Biotherapeutics is developing iPSC-derived NK cells using mRNA gene-editing for cancer treatment.

Fate Therapeutics is developing iPSC-derived NK and CAR-T cells for cancer and immune disorders.

FUJIFILM Cellular Dynamics, Inc. supports iPSC-derived cell therapy development through its production facility.

GC Therapeutics (GCTx) uses its TFome platform to develop iPSC-based therapies for neurological and immune diseases.

Gameto is developing iPSC-derived solutions to mature eggs for IVF and egg freezing.

Go Liver Therapeutics is developing iPSC-derived liver therapies for regenerative medicine.

Greenstone Bio is using AI and patient-derived iPSCs to accelerate drug discovery.

Heartseed Inc. is developing iPSC-derived cardiomyocytes for treating heart failure.

Healios K.K. is conducting clinical trials using iPSC-derived retinal cells to treat macular degeneration.

Hebecell is commercializing allogeneic iPSC-derived NK cell therapies for cancer treatment.

Hopstem Biotechnology is developing iPSC-derived therapies for ocular diseases in partnership with Neurophth Biotechnology.

Implant Therapeutics is developing hypo-immunogenic iPSC-derived MSCs for ex-vivo gene therapy.

IN8bio is reprogramming donor cells into iPSCs to differentiate into gamma-delta T cells for cancer immunotherapy.

I Peace Inc. and Avery Therapeutics are advancing an iPSC-derived heart failure therapy.

Ipsell is using iPSCs for cell line production and disease modeling to develop stem cell-based treatments.

IPS HEART is developing iPSC-derived heart muscle for treating heart disease, including Duchenne Cardiomyopathy.

iPSirius SAS is developing a cancer vaccine leveraging iPSCs and cancer stem cell similarities.

iRegene Therapeutics is developing iPSC-derived treatments for Parkinson’s and retinal diseases using AI and chemical induction.

Jacobio Pharmaceuticals is partnering with Hebecell to develop iPSC-derived NK cells for cancer treatment.

Kenai Therapeutics is developing iPSC-derived dopamine progenitor cells for Parkinson’s disease.

Keio University is conducting a trial using iPSC-derived therapies for spinal cord injuries.

Kiji Therapeutics is developing engineered iPSC-derived MSCs for various therapeutic applications.

Kyoto University Hospital is conducting a trial using iPSC-derived dopaminergic progenitors for Parkinson’s disease.

Laverock Therapeutics is developing iPSC-derived cell therapies with improved efficacy through gene editing.

Neurophth Biotechnology Ltd. is developing iPSC-derived therapies for retinal diseases in collaboration with Hopstem Biotechnology.

Notch Therapeutics is developing iPSC-derived T-cells for hematological malignancies in partnership with Allogene Therapeutics.

Novo Nordisk is co-developing iPSC-derived heart failure therapies with Heartseed.

Osaka University developed iPS-derived corneal cell sheets for patients with limbal stem cell deficiency.

Pluristyx and panCELLa merged to create genetically modified, “off-the-shelf” iPSCs for cell therapy.

REPROCELL offers a “Personal iPS service” to store individual iPSCs for future medical use.

RIKEN pioneered the world’s first iPSC-derived therapeutic cell transplant for AMD in 2014.

RheinCell Therapeutics GmbH manufactures GMP-compliant iPSCs from HLA-homozygous umbilical cord blood.

RxCell Inc. develops universal iPSC lines for allogeneic therapies, including retinal disorders.

Ryne Biotechnology, Inc. is developing iPSC-derived dopamine neurons for Parkinson’s disease therapy.

Sana Biotechnology is developing hypoimmune-modified iPSCs to avoid immune rejection in allogeneic therapies.

SCG Cell Therapy Pte Ltd is using iPSC technology to expand its NK cell therapy portfolio.

SCM Lifescience has licensed iPSC-based diabetic cell therapies developed by Allele Biotechnology.

Semma Therapeutics, acquired by Vertex Pharmaceuticals, is developing iPSC-derived pancreatic cells for Type 1 diabetes.

Shinobi Therapeutics is developing hypo-immune iPSC-derived T cells for cancer therapy using immune evasion.

Shoreline Biosciences is developing allogeneic iPSC-derived NK and macrophage therapies for cancer and other diseases.

StemSight is developing iPSC-based therapies for corneal blindness.

Stemson Therapeutics is developing a therapy to create de novo hair follicles for hair loss treatment.

Thyas Co. Ltd. is developing iPS-T and iPS-NK cell therapies for cancer treatment.

Tolerance Bio is developing an iPSC-based thymus cell therapy platform for immune diseases.

TreeFrog Therapeutics is developing iPSC-derived therapies and supports co-development through its manufacturing platform.

The U.S. NIH is conducting the first U.S. clinical trial of an iPSC-derived therapeutic for advanced-stage geographic atrophy of the eye.

VCCT Inc. is developing ex vivo and in vivo cell therapy solutions for ocular diseases using iPSCs.

Vision Care Group is focused on iPSC-derived therapeutics for retinal diseases.

Vita Therapeutics, a Cambrian Biopharma affiliate, is developing genetically engineered iPSC-derived treatments for muscular dystrophy.